Marcia Belvin - Sep 20, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Stock symbol
CTMX
Transactions as of
Sep 20, 2023
Transactions value $
-$5,356
Form type
4
Date filed
9/22/2023, 07:16 PM
Previous filing
Mar 29, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +11.3K +7.99% $0.00 152K Sep 20, 2023 Direct F1, F2
transaction CTMX Common Stock Sale -$5.36K -4.12K -2.71% $1.30 148K Sep 22, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
F2 Includes 116,875 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.